Form C: Issuer Information

Issuer Information

Name of Issuer:

DGN Pharmacy, Inc.

Check box if Amendment is material and investors will have five business days to reconfirm

Describe the Nature of the Amendment:

Updated officers, voting power, risks, cap table, past raises, and financial condition. Added CPA reviewed financial statements for 2020 and a Lead Investor, Clarified that New Series Preferred Stock would be junior in liquidation preference.

Legal Status of Issuer:

Form:

Corporation

Jurisdiction of Incorporation/Organization:

NEW JERSEY

Date of Incorporation/Organization:

04-17-2009

Physical Address of Issuer:

Address 1:

20 Murray Hill Parkway

Address 2:

Suite 210

City:

East Rutherford

State/Country:

NEW JERSEY

Mailing Zip/Postal Code:

07073

Website of Issuer:

https://www.personalrx.com/

Is there a Co-issuer?

Yes

Intermediary through which the Offering will be Conducted:

CIK:

0001670254

Company Name:

Wefunder Portal LLC

Commission File Number:

007-00033

CRD Number:

283503

Form C: Offering Information

Offering Information

Amount of compensation to be paid to the intermediary, whether as a dollar amount or a percentage of the offering amount, or a good faith estimate if the exact amount is not available at the time of the filing, for conducting the offering, including the amount of referral and any other fees associated with the offering:

7.5% of the offering amount upon a successful fundraise, and be entitled to reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering.

Any other financial interest in the issuer held by the intermediary, or any arrangement for the intermediary to acquire such an interest:

Type of Security Offered:

Other

Specify:

Simple Agreement for Future Equity (SAFE)

Target Number of Securities to be Offered:

50000

Price:

1.00000

Price (or Method for Determining Price):

Pro-rated portion of the total principal value of $50,000; interests will be sold in increments of $1; each investment is convertible to one share of stock as described under Item 13.

Target Offering Amount:

50000.00

Maximum Offering Amount (if different from Target Offering Amount):

1070000.00

Oversubscriptions Accepted:

Yes

If yes, disclose how oversubscriptions will be allocated:

Other

Provide a description:

As determined by the issuer

Deadline to reach the Target Offering Amount:

12-31-2021

NOTE: If the sum of the investment commitments does not equal or exceed the target offering amount at the offering deadline, no securities will be sold in the offering, investment commitments will be cancelled and committed funds will be returned.

Form C: Annual Report Disclosure Requirements

Annual Report Disclosure Requirements

Current Number of Employees:

Total Assets Most Recent Fiscal Year-end:

1560679.00

Total Assets Prior Fiscal Year-end:

1153852.00

Cash and Cash Equivalents Most Recent Fiscal Year-end:

136.00

Cash and Cash Equivalents Prior Fiscal Year-end:

77.00

Accounts Receivable Most Recent Fiscal Year-end:

54702.00

Accounts Receivable Prior Fiscal Year-end:

84878.00

Short-term Debt Most Recent Fiscal Year-end:

5533007.00

Short-term Debt Prior Fiscal Year-end:

2696702.00

Long-term Debt Most Recent Fiscal Year-end:

8969990.00

Long-term Debt Prior Fiscal Year-end:

7669353.00

Revenue/Sales Most Recent Fiscal Year-end:

1670999.00

Revenue/Sales Prior Fiscal Year-end:

1549232.00

Cost of Goods Sold Most Recent Fiscal Year-end:

1527448.00

Cost of Goods Sold Prior Fiscal Year-end:

1486540.00

Taxes Paid Most Recent Fiscal Year-end:

0.00

Taxes Paid Prior Fiscal Year-end:

0.00

Net Income Most Recent Fiscal Year-end:

-3730113.00

Net Income Prior Fiscal Year-end:

-2803932.00